文献速递产科母胎医学

胎儿X连锁鱼鳞病产前筛查:NIPT与母血清uE3联合策略的大队列研究

Prenatal Screening for Fetal X-Linked Ichthyosis: A Large Cohort Study Combining Non-Invasive Prenatal Testing and Maternal Serum Unconjugated Estriol Analysis.
PubMed 文献 · Prenat Diagn · 2026-03-26

该回顾性队列纳入95485例筛查孕妇,识别147例孕中期uE3低值(MoM≤0.3)病例,其中41例接受NIPT检测母体Xp22.31微缺失。Group 1(uE3≤0.1)确诊XLI发生率49.3%(35/71),显著高于Group 2(0.1<uE3≤0.3)的1.3%(1/76);NIPT检出28例母体缺失,联合极低uE3时XLI阳性预测值达100%。结论认为NIPT母体CNV检测联合uE3可提高XLI产前筛查准确性。

要点

  • 孕中期uE3 MoM≤0.1时男性胎儿XLI发生率49.3%,显著高于0.1<MoM≤0.3的1.3%。
  • NIPT检出母体Xp22.31缺失联合极低uE3时,XLI阳性预测值达100%。
  • 联合策略在超声正常、极低uE3且有孤立XLI家族史的男性胎儿中最具临床可行性。

核心结论

  • NIPT母体CNV检测联合母血清uE3定量可显著提高男性胎儿XLI产前筛查准确性。
  • 联合策略在超声正常、极低uE3且家族史阳性的男性胎儿场景下最具临床可操作性。

研究设计与样本

  • 回顾性队列研究,筛查孕妇95485例,识别147例孕中期uE3 MoM≤0.3病例。
  • 按uE3 MoM分层:Group 1(uE3≤0.1,71例)与Group 2(0.1<uE3≤0.3,76例)。
  • 41例接受NIPT检测母体Xp22.31微缺失(含STS基因)。
  • 胎儿基因型经羊水CMA验证,未产前诊断者用新生儿足跟血STS特异性PCR验证。

主要发现

  • Group 1确诊XLI发生率49.3%(35/71),Group 2为1.3%(1/76),差异显著。
  • 41例NIPT中检出28例母体Xp22.31缺失。
  • 母体缺失联合极低uE3(MoM≤0.3)时XLI阳性预测值达100%。
  • 该联合策略阳性预测值明显高于单用NIPT(理论约50%)或单用uE3筛查(49.3%)。

关键数值与推荐

  • uE3低值定义:孕中期MoM≤0.3。
  • Group 1:uE3 MoM≤0.1;Group 2:0.1<uE3 MoM≤0.3。
  • Group 1 XLI发生率49.3%(35/71),Group 2为1.3%(1/76)。
  • NIPT联合极低uE3的XLI阳性预测值为100%。
  • 单用uE3筛查阳性预测值为49.3%,单用NIPT理论阳性预测值约50%。

临床怎么用

  • 对孕中期uE3 MoM≤0.3的孕妇,尤其MoM≤0.1者,应警惕男性胎儿XLI风险。
  • 可对uE3低值孕妇行NIPT检测母体Xp22.31微缺失,辅助判断胎儿XLI风险。
  • 超声正常、极低uE3且孤立XLI家族史的男性胎儿是联合筛查最具行动性的场景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to evaluated the clinical utility of an integrated prenatal screening strategy combining non-invasive prenatal testing (NIPT) and maternal serum unconjugated estriol (uE3) quantification for detecting X-linked ichthyosis (XLI) in male fetuses. METHODS: Within a retrospective cohort of 95,485 screened pregnancies, 147 cases exhibiting low second-trimester uE3 levels (Multiple of the Median, MoM ≤ 0.3) were identified. Participants were stratified based on uE3 MoM values into Group 1 (uE3 ≤ 0.1) and Group 2 (0.1 < uE3 ≤ 0.3). NIPT was performed in 41 cases to detect maternal Xp22.31 microdeletions encompassing the STS gene. Fetal genotypes were verified via chromosomal microarray analysis (CMA) of amniotic fluid in cases opting for invasive prenatal diagnosis. For those without prenatal diagnosis, verification was conducted by STS-specific PCR using newborn heel blood samples. RESULTS: The incidence of confirmed XLI was significantly higher in Group 1 (49.3%, 35/71) than in Group 2 (1.3%, 1/76). Among the 41 cases that underwent NIPT, maternal Xp22.31 deletions were detected in 28 cases. When this deletion combined with an extremely low maternal serum uE3 level (MoM ≤ 0.3), the positive predictive value for XLI reached 100%, which was markedly higher than that of NIPT alone (theoretical ∼50% PPV) or uE3 screening alone (49.3% PPV). CONCLUSION: Integrating NIPT-based maternal CNV detection with maternal serum uE3 quantification significantly improves the accuracy of prenatal XLI screening. This combined approach is most clinically actionable in a specific scenario: a male fetus presenting with normal ultrasound findings, extremely low maternal uE3, and a positive family history of isolated XLI without comorbidities.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Han M, Chen M, Du Y, et al. Prenatal Screening for Fetal X-Linked Ichthyosis: A Large Cohort Study Combining Non-Invasive Prenatal Testing and Maternal Serum Unconjugated Estriol Analysis. Prenat Diagn. 2026. PMID: 41888405. doi:10.1002/pd.70139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。